Related Experiment Video
Updated: May 13, 2026

10:44
A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
Published on: August 9, 2019
Immunosympathectomy as the first phenotypic knockout with antibodies
1Bio@SNS Laboratory, Scuola Normale Superiore, 56126 Pisa, Italy. a.cattaneo@ebri.it
Summary
Rita Levi-Montalcini proved endogenous nerve growth factor (NGF) sustains sympathetic neurons. This 1960 PNAS study used antibodies for targeted neuronal ablation, advancing biological research.
Area of Science:
- Neuroscience
- Developmental Biology
- Immunology
Background:
- A 1960 PNAS article by Rita Levi-Montalcini provided definitive evidence for endogenous nerve growth factor (NGF).
- The research demonstrated NGF's crucial role in the survival of sympathetic neurons in vivo.
- This followed a decade of work showing a tumor-secreted factor stimulated nerve fiber outgrowth.
Discussion:
- The study pioneered targeted loss-of-function experiments to validate biological molecule functions.
- It showcased precise neuronal subpopulation ablation using immunological methods.
- The work is contextualized within the NGF discovery timeline and Levi-Montalcini's career.
Key Insights:
- Endogenous NGF is essential for sympathetic neuron survival.
- Antibody-mediated phenotypic knockout in vivo is a powerful research tool.
- This methodology foreshadowed later advancements in antibody technologies.
Outlook:
- The foundational work on NGF and antibody-based knockout has lasting implications.
- It paved the way for monoclonal antibodies and recombinant antibody technologies.
- The research continues to inspire new approaches in neuroscience and molecular biology.
Related Concept Videos
In-vitro Mutagenesis
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

